cally that changes in established practice would be opposed.
A major disadvantage of standardising glomerular filtration rate to surface area is that formulas for estimating surface area from weight or weight and length are based on relatively few actual measurements in the smallest weight range and have never been systematically tested in babies of varying body proportions. Practical neonatal management decisions, including those regarding calorie intake, temperature control, and fluid, electrolyte, and drug administration are almost universally made on the basis of body weight, which can be measured directly. Even workers who standardise their glomerular filtration rate results/mi2 generally calculate the doses of their test substances per kg body weight. For research findings to be usefully assimilated and applied clinically, they should be expressed in the same way as other parameters.
It has been argued that it would be logical to relate glomerular filtration rate to the size of the fluid pool affected by the kidney5 6 but this has three disadvantages. Firstly, like surface area, fluid volumes would be estimated rather than measured. Secondly, no single fluid space would be appropriate to all aspects of renal function; total body water would be best for urea and water handling,5 and extracellular fluid volume for inulin or mannitol clearances.6 Thirdly, like surface area:weight, the total body water:weight and extracellular fluid volume:weight ratios fall with increasing postconceptual age, exaggerating the rises in glomerular filtration rate with increasing body size.
We have shown that weight, the only reference standard that can be actually measured and is clinically useful, is the best index for neonatal glomerular filtration rate measurement. To expect a single standard to apply to all patients weighing from 1 to 70 kg is simplistic, however, and could be misleading. It is better to consider glomerular filtration rate/kg as useful in the newborn period and glomerular filtration rate/mi2 as convenient in older children, and not to place physiological importance on either approach. The aetiology of Cushing's syndrome can usually be determined from the serum adrenocorticotrophic hormone concentration and the response of urinary corticosteroids to high dose dexamethasone and metyrapone. ' In some circumstances, however, these investigations may be misleading. 2 We report a patient who seemed to have pituitary dependent hypercortisolism but was subsequently shown to have an adrenocorticotrophic hormone secreting bronchial carcinoid tumour. group.bmj.com on September 20, 2017 -Published by http://adc.bmj.com/ Downloaded from costeroids are unaffected by high dose dexamethasone and metyrapone.
In our patient, the adrenal function tests were so consistent with pituitary disease that the pulmonary lesion was initially thought to be coincidental. However, the resolution of hypercortisolism after excision of a tumour, known in adults3 to be associated with the ectopic adrenocorticotrophic hormone syndrome, and the finding of adrenocorticotrophic hormone and related peptides in the tumour, confirmed the diagnosis of ectopic adrenocorticotrophic hormone secretion.
Serum 
Patients
The group comprised 6 girls and two boys aged 3 to 29 years (mean 13.5 years). The diagnosis of cystic fibrosis had been made on the basis of clinical and radiological findings, and raised sweat electrolyte measurements. At the onset of joint disease, pulmonary disease was mild in five patients, moderate in two, and advanced in one. Six patients were taking pancreatic enzyme preparations; five had Pseudomonas aeruginosa in their sputum cultures; and 6 were taking oral antibiotics continuously, two on a sporadic basis. Clubbing of varying severity was present in all patients, however, none had long bone pain or radiological evidence of periosteal elevation. 
